Effects of high-intensity interval training (HIIT) and sprint interval training (SIT) on fat oxidation during exercise: a systematic review and meta-analysis.

OBJECTIVE: To investigate the effects of high-intensity interval training (HIIT) and sprint interval training (SIT) on fat oxidation during exercise (FatOx) and how they compare with the effects of moderate-intensity continuous training (MICT). DESIGN: Systematic review and meta-analysis. DATA SOURCES: Academic Search Ultimate, CINAHL, Networked Digital Library of Theses and Dissertations, Open Access Theses and Dissertations, OpenDissertations, PubMed/MEDLINE, Scopus, SPORTDiscus and Web of Science. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Studies using a between-group design, involving adult participants who were not trained athletes, and evaluating effects of HIIT or SIT on FatOx (vs no exercise or MICT) were included. RESULTS: Eighteen studies of fair-to-good quality were included; nine comparing HIIT or SIT with no exercise and eleven comparing HIIT or SIT with MICT. A significant pooled effect of these types of interval training on FatOx was found (mean difference in g/min (MD)=0.08; 95% confidence interval (CI) 0.04 to 0.12; p<0.001). Significant effects were found for exercise regimens lasting ≥4 weeks, and they increased with every additional week of training (ß=0.01; 95% CI 0.00 to 0.02; p=0.003). HIIT and/or SIT were slightly more effective than MICT (MD=0.03; 95% CI 0.01 to 0.05; p=0.005). The effects on FatOx were larger among individuals with overweight/obesity. CONCLUSION: Engaging in HIIT or SIT can improve FatOx, with larger effects expected for longer training regimens and individuals with overweight/obesity. While some effects seem small, they may be important in holistic approaches to enhance metabolic health and manage obesity.

Acute Effects of High-Intensity Interval Exercise While Wearing a Sauna Suit on Energy Expenditure and Excess Post-exercise Oxygen Consumption.

ABSTRACT: Matthews, ARD, Astorino, TA, Crocker, GH, and Sheard, AC. Acute effects of high-intensity interval exercise while wearing a sauna suit on energy expenditure and excess post-exercise oxygen consumption. J Strength Cond Res 36(9): 2427-2433, 2022-The use of sauna suits has increased because of claims that they enhance weight loss and increase body temperature during exercise. Therefore, the purpose of this study was to examine changes in energy expenditure (EE) and excess post-exercise oxygen consumption (EPOC) in response to high-intensity interval exercise (HIIE) while wearing a sauna suit. Twelve recreationally active men and women age = (28.7 ± 6.0 years) initially completed assessment of resting metabolic rate and maximal oxygen uptake. On two separate days, subjects completed HIIE consisting of ten 1-minute intervals at 85% peak power output, both with and without a sauna suit. Oxygen consumption, heart rate, and core temperature were continuously measured during and 1 hour after exercise. Energy expenditure during (285 ± 57 kcal vs. 271 ± 58 kcal) and post-exercise (123 ± 30 kcal vs. 113 ± 16 kcal) was significantly higher ( p = 0.025) with a sauna suit than without a sauna suit. However, EPOC (6.19 ± 4.46 L of O 2 vs. 4.25 ± 3.36 L of O 2 ; p = 0.05) was not significantly different 1 hour after exercise, and core temperature was similar ( p = 0.62) between conditions. Fat oxidation was significantly increased for 60 minutes after HIIE with a sauna suit ( p = 0.009). Wearing a sauna suit during HIIE elicits greater EE vs. not wearing a sauna suit, but the increase of 23 kcal may not benefit weight loss.

Chronic activity-based therapy does not improve body composition, insulin-like growth factor-I, adiponectin, or myostatin in persons with spinal cord injury.

UNLABELLED: Spinal cord injury (SCI) induces dramatic changes in body composition including reductions in fat-free mass (FFM) and increases in fat mass (FM). OBJECTIVE: To examine changes in body composition in response to chronic activity-based therapy (ABT) in persons with SCI. DESIGN: Longitudinal exercise intervention. METHODS: Seventeen men and women with SCI (mean age=36.1±11.5 years) completed 6 months of supervised ABT consisting of load bearing, resistance training, locomotor training, and functional electrical stimulation. At baseline and after 3 and 6 months of ABT, body weight, body fat, and FFM were assessed using dual-energy X-ray absorptiometry, and fasting blood samples were obtained to assess changes in insulin-like growth factor-I (IGF-I), adiponectin, and myostatin. RESULTS: Across all subjects, there was no change (P>0.05) in body weight, percent body fat, or FFM of the leg, arm, or trunk, whereas whole-body FFM declined (P=0.02, 50.4±8.4 to 49.2±7.4 kg). No changes (P=0.21-0.41) were demonstrated in IGF-I, adiponectin, or myostatin during the study. CONCLUSIONS: Chronic ABT focusing on the lower extremity does not slow muscle atrophy or alter body fat, body mass, or regional depots of FFM in persons with SCI. Further, it does not induce beneficial changes in adiponectin, myostatin, or IGF-I. Alternative exercise-based therapies are needed in SCI to reverse muscle atrophy and minimize the onset of related health risks.

A systematic review of the efficacy of ergogenic aids for improving running performance.

Running is a common form of activity worldwide, and participants range from "weekend warriors" to Olympians. Unfortunately, few studies have examined efficacy of various ergogenic aids in runners because the majority of the literature consists of cycling-based protocols, which do not relate to running performance. The majority of running studies conducted markedly vary in regards to specific distance completed, subject fitness level, and effectiveness of the ergogenic aid examined. The aim of this article was to systematically examine the literature concerning utility of several ergogenic aids on middle-distance running (400-5,000 m) and long-distance running (10,000 meters marathon = 42.2 km) performance. In addition, this article highlights the dearth of running-specific studies in the literature and addresses recommendations for future research to optimize running performance through nutritional intervention. Results revealed 23 studies examining effects of various ergogenic aids on running performance, with a mean Physiotherapy Evidence Database score equal to 7.85 ± 0.70. Of these studies, 71% (n = 15) demonstrated improved running performance with ergogenic aid ingestion when compared with a placebo trial. The most effective ergogenic aids for distances from 400 m to 40 km included sodium bicarbonate (4 studies; 1.5 ± 1.1% improvement), sodium citrate (6 studies; 0.3 ± 1.7% improvement), caffeine (CAFF) (7 studies; 1.1 ± 0.4% improvement), and carbohydrate (CHO) (6 studies; 4.1 ± 4.4% improvement). Therefore, runners may benefit from ingestion of sodium bicarbonate to enhance middle distance performance and caffeine and carbohydrate to enhance performance at multiple distances.

Increases in cycling performance in response to caffeine ingestion are repeatable.

The primary aim of this study was to determine the repeatability of caffeine's ergogenic effects on cycling performance. It was hypothesized that improvements in performance would be similar when caffeine was ingested on 2 separate days. Nine endurance-trained men and women (mean age and maximal oxygen uptake, 27.4 ± 5.9 years and 57.5 ± 3.9 mL kg⁻¹ min⁻¹) initially completed 2 familiarization trials. During 3 subsequent sessions separated by at least 48 hours, the subjects completed a 10-km cycling time trial preceded by ingestion of a drink containing caffeine (5 mg/kg) or placebo. Treatments were ingested using a randomized, single-blind, crossover design, and the subjects were deceived as to the specific content of all drinks. During exercise, heart rate, rating of perceived exertion, and time were recorded every 1.6 km. Repeated-measures analysis of variance was used to compare the differences in variables across distance and treatment. In both caffeine trials, caffeine increased (P = .02) cycling performance by 1.6% and 1.9% vs placebo (16.98 ± 0.96 and 16.92 ± 0.97 minutes with caffeine vs 17.25 ± 0.96 minutes in placebo), and 7 of 9 subjects revealed improved performance. The mean performance improvement in the caffeine trials was similar (P = .35; -0.27 and -0.32 minutes, respectively) across days. Heart rate during exercise was higher (P b .001) with caffeine vs placebo, although the rating of perceived exertion was similar (P = .65). Data reveal that caffeine's ergogenic effects on cycling performance are repeatable across days, yet some individuals did not exhibit improved performance with caffeine.

Is running performance enhanced with creatine serum ingestion?

Runners Advantage (RA) creatine (Cr) serum has been marketed to increase running performance. To test this claim, cross-country runners completed baseline testing (BASE), an outdoor 5,000-m run followed by treadmill Vo(2)max testing on the same day. Subjects repeated testing after ingesting 5 ml of RA (n = 13) containing 2.5 g of Cr or placebo (n = 11). Heart rate (HR), rating of perceived exertion (RPE), and run time were recorded. With RA (56.48 +/- 8.93 ml.kg(-1.)min(-1)), Vo(2)max was higher (p = 0.01) vs. BASE (54.07 +/- 9.36 ml.kg(-1.)min(-1)), yet the magnitude of the increase was within the coefficient of variation of Vo(2)max. No effect of RA on maximal HR was exhibited, yet Vco(2)max and duration of incremental exercise were significantly higher (p < 0.025) vs. BASE. Vo(2)max was similar in PL (58.85 +/- 6.67 ml.kg(-1).min(-1)) and BASE (57.28 +/- 7.22 ml.kg(-1.)min(-1)). With RA, the 5,000-m time was unchanged, and RPE was lower (p < 0.025) vs. BASE. These data do not support the ergogenic claims of RA in its current form and dose.